{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:14:20Z","timestamp":1789492460822,"version":"build-2803163510"},"reference-count":130,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jhep.2026.02.030","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:36:41Z","timestamp":1782992201000},"page":"794-807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic therapy of biliary tract cancer: The road to personalised strategies"],"prefix":"10.1016","volume":"85","author":[{"given":"Angela","family":"Lamarca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7029-4310","authenticated-orcid":false,"given":"James J.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jhep.2026.02.030_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.jhep.2026.02.030_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"10391","key":"10.1016\/j.jhep.2026.02.030_bib3","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.02.030_bib4","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","author":"Kendre","year":"2022","journal-title":"J Hepatol"},{"issue":"14","key":"10.1016\/j.jhep.2026.02.030_bib5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jhep.2026.02.030_bib6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.jhep.2026.02.030_bib7","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jhep.2026.02.030_bib8","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO-24-01383","article-title":"A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"43","author":"Shroff","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jhep.2026.02.030_bib9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"2","key":"10.1016\/j.jhep.2026.02.030_bib10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jhep.2025.01.040","article-title":"A phase III randomized study of first-line NUC-1031\/cisplatin vs. gemcitabine\/cisplatin in advanced biliary tract cancer","volume":"83","author":"Knox","year":"2025","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2026.02.030_bib11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","article-title":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jhep.2026.02.030_bib12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jhep.2026.02.030_bib13","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cncr.29778","article-title":"Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: a randomized phase 2 trial (Vecti-BIL study)","volume":"122","author":"Leone","year":"2016","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.jhep.2026.02.030_bib14","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S1470-2045(21)00409-5","article-title":"Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study","volume":"22","author":"Valle","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jhep.2026.02.030_bib15","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"25","key":"10.1016\/j.jhep.2026.02.030_bib16","first-page":"2201","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"S0168\u20138278","author":"Oh","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.02.030_bib17","article-title":"Maintenance chemotherapy in biliary tract tumours in the era of immuno-chemotherapy","volume":"7","author":"Lamarca","year":"2025","journal-title":"ESMO Gastrointest Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jhep.2026.02.030_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4093","article-title":"Three-year follow-up data from KEYNOTE-966: pembrolizumab (pembro) plus gemcitabine and cisplatin (gem\/cis) compared with gem\/cis alone for patients (pts) with advanced biliary tract cancer (BTC)","volume":"42","author":"Finn","year":"2024","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.jhep.2026.02.030_bib19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u2018prime time\u2019 in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.02.030_bib20","article-title":"Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT 202","author":"Vogel","year":"2023","journal-title":"World GI"},{"issue":"15_suppl","key":"10.1016\/j.jhep.2026.02.030_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e16686","article-title":"The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA)","volume":"38","author":"Goyal","year":"2020","journal-title":"JCO"},{"issue":"9","key":"10.1016\/j.jhep.2026.02.030_bib22","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/humu.22825","article-title":"Evaluation of hybridization capture versus amplicon-based methods for whole-exome sequencing","volume":"36","author":"Samorodnitsky","year":"2015","journal-title":"Hum Mutat"},{"issue":"8","key":"10.1016\/j.jhep.2026.02.030_bib23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/14737159.2025.2521538","article-title":"From barriers to solutions: an expert-based algorithm for cholangiocarcinoma and other biliary tract cancers testing in the Era of precision oncology","volume":"25","author":"Stenzinger","year":"2025","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"10.1016\/j.jhep.2026.02.030_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1016\/j.jhep.2026.02.030_bib25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.02.030_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.04.443","article-title":"O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT-202","volume":"33","author":"Vogel","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.jhep.2026.02.030_bib27","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2026.02.030_bib28","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discov"},{"issue":"2_suppl","key":"10.1016\/j.jhep.2026.02.030_bib29","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.2_suppl.476","article-title":"Efficacy and safety of lirafugratinib in FGFRi -na\u00efve cholangiocarcinoma (CCA) patients harboring FGFR2 fusions\/rearrangements (FGFR2 f\/r)","volume":"44","author":"Hollebecque","year":"2026","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jhep.2026.02.030_bib30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1158\/1535-7163.MCT-22-0012","article-title":"Tinengotinib (TT-00420), a novel spectrum-selective small-molecule kinase inhibitor, is highly active against triple-negative breast cancer","volume":"22","author":"Peng","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"10.1016\/j.jhep.2026.02.030_bib31","article-title":"Clinical development and management of adverse events associated with FGFR inhibitors","volume":"4","author":"Subbiah","year":"2023","journal-title":"CR Med"},{"issue":"30","key":"10.1016\/j.jhep.2026.02.030_bib32","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2217\/fon-2020-0299","article-title":"Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions\/translocations: the PROOF 301 trial","volume":"16","author":"Makawita","year":"2020","journal-title":"Future Oncol"},{"issue":"30","key":"10.1016\/j.jhep.2026.02.030_bib33","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2217\/fon-2020-0429","article-title":"FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements","volume":"16","author":"Bekaii-Saab","year":"2020","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.jhep.2026.02.030_bib34","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"issue":"22","key":"10.1016\/j.jhep.2026.02.030_bib35","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib is a novel irreversible FGFR 1\u20134 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.jhep.2026.02.030_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4097","article-title":"FOENIX-CCA2 quality of life data for futibatinib-treated intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions\/rearrangements","volume":"39","author":"Valle","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jhep.2026.02.030_bib37","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jhep.2026.02.030_bib38","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S2468-1253(24)00119-5","volume":"9","author":"Vogel","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"15_suppl","key":"10.1016\/j.jhep.2026.02.030_bib39","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4089","article-title":"Natural history of patients (pts) with advanced cholangiocarcinoma (CCA) with FGFR2 gene fusion\/rearrangement or wild-type (WT) FGFR2","volume":"39","author":"Shroff","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.jhep.2026.02.030_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102627","article-title":"Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma","volume":"121","author":"Lamarca","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"suppl_7","key":"10.1016\/j.jhep.2026.02.030_bib41","first-page":"S808","article-title":"Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f\/r), FGFR inhibitor (FGFRi)-na\u00efve cholangiocarcinoma (CCA): ReFocus trial","volume":"33","author":"Hollebecque","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jhep.2026.02.030_bib42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2468-1253(25)00230-4","article-title":"Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial","volume":"11","author":"Javle","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2026.02.030_bib43","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/2159-8290.CD-20-1669","article-title":"FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma","volume":"11","author":"Cleary","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2026.02.030_bib44","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2026.02.030_bib45","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2026.02.030_bib46","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.02.030_bib47","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2026.02.030_bib48","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/nature09132","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"465","author":"Dang","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2026.02.030_bib49","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.2217\/fon-2020-1274","article-title":"Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma","volume":"17","author":"Aguado-Fraile","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.jhep.2026.02.030_bib50","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S2468-1253(19)30189-X","article-title":"Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study","volume":"4","author":"Lowery","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.02.030_bib51","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy)","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.02.030_bib52","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2026.02.030_bib53","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2026.02.030_bib54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41698-022-00304-5","article-title":"Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma","volume":"6","author":"Cleary","year":"2022","journal-title":"NPJ Precision Oncol"},{"key":"10.1016\/j.jhep.2026.02.030_bib55","doi-asserted-by":"crossref","unstructured":"Cowzer D. et al. Clinical utility and prognostic implications of circulating cell-free DNA in biliary tract cancer JCO Precis Oncol. 9:e2500355. doi:10.1200\/PO-25-00355.","DOI":"10.1200\/PO-25-00355"},{"key":"10.1016\/j.jhep.2026.02.030_bib56","doi-asserted-by":"crossref","unstructured":"Lapin M. et al. Monitoring of dynamic changes and clonal evolution in circulating tumor DNA from patients with IDH-mutated cholangiocarcinoma treated with isocitrate dehydrogenase inhibitors JCO Precis Oncol. 6:e2100197. doi:10.1200\/PO.21.00197.","DOI":"10.1200\/PO.21.00197"},{"key":"10.1016\/j.jhep.2026.02.030_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2026.02.030_bib58","doi-asserted-by":"crossref","unstructured":"Sulkowski P. L. et al Oncometabolites suppress DNA repair by disrupting local chromatin signalling Nature. 582:586\u2013591. doi:10.1038\/s41586-020-2363-0.","DOI":"10.1038\/s41586-020-2363-0"},{"key":"10.1016\/j.jhep.2026.02.030_bib59","doi-asserted-by":"crossref","unstructured":"Schvartzman J. M. et al Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination Mol Cel. 83:2347\u20132356. doi:10.1016\/j.molcel.2023.05.026.","DOI":"10.1016\/j.molcel.2023.05.026"},{"key":"10.1016\/j.jhep.2026.02.030_bib60","doi-asserted-by":"crossref","unstructured":"Wu M. J. et al Mutant IDH inhibits IFNgamma-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma Cancer Discov. 12:812\u2013835. doi:10.1158\/2159-8290.CD-21-1077.","DOI":"10.1158\/2159-8290.CD-21-1077"},{"key":"10.1016\/j.jhep.2026.02.030_bib61","doi-asserted-by":"crossref","unstructured":"Zabransky D. J. et al Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1- mutant cholangiocarcinoma Hepatology. 82:599\u2013611. doi:10.1097\/HEP.0000000000001185.","DOI":"10.1097\/HEP.0000000000001185"},{"key":"10.1016\/j.jhep.2026.02.030_bib62","series-title":"Advanced solid tumors harboring IDH1 or IDH2 mutations clin cancer res","article-title":"Final results from a first-in-human phase 1 study of the dual isocitrate dehydrogenase (IDH) 1\/2 inhibitor, LY3410738","author":"Harding","year":"2025"},{"key":"10.1016\/j.jhep.2026.02.030_bib63","doi-asserted-by":"crossref","unstructured":"DiNardo C. D. et al A phase 1 study of IDH305 in patients with IDH1(R132)-mutant acute myeloid leukemia or myelodysplastic syndrome J Cancer Res Clin Oncol. 149:1145\u20131158. doi:10.1007\/s00432-022-03983-6.","DOI":"10.1007\/s00432-022-03983-6"},{"key":"10.1016\/j.jhep.2026.02.030_bib64","doi-asserted-by":"crossref","unstructured":"Wick A. et al. Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors Clin Cancer Res. 27:2723\u20132733. doi:10.1158\/1078-0432.CCR-20-4256.","DOI":"10.1158\/1078-0432.CCR-20-4256"},{"key":"10.1016\/j.jhep.2026.02.030_bib65","doi-asserted-by":"crossref","unstructured":"Cortes J. et al. Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort J Hematol Oncol. 18:102. doi:10.1186\/s13045-025-01751-w.","DOI":"10.1186\/s13045-025-01751-w"},{"key":"10.1016\/j.jhep.2026.02.030_bib66","doi-asserted-by":"crossref","unstructured":"Cecchini M. et al. Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: safety and antitumor activity from the phase 2 Natl Cancer Inst 10129 trial Cancer. 131:e35755. doi:10.1002\/cncr.35755.","DOI":"10.1002\/cncr.35755"},{"key":"10.1016\/j.jhep.2026.02.030_bib67","doi-asserted-by":"crossref","unstructured":"Notarangelo G. et al. Oncometabolite d-2HG alters T cell metabolism to impair CD8(+) T cell function Science. 377:1519\u20131529. doi:10.1126\/science.abj5104.","DOI":"10.1126\/science.abj5104"},{"key":"10.1016\/j.jhep.2026.02.030_bib68","author":"Nguyen","year":"2025","journal-title":"Clin translational Study ivosidenib plus nivolumab Adv Solid tumors harboring IDH1 mutations Oncologist 30"},{"issue":"1","key":"10.1016\/j.jhep.2026.02.030_bib69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.jhep.2026.02.030_bib70","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","article-title":"HER2-targeted therapies beyond breast cancer - an update","volume":"21","author":"Yoon","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2026.02.030_bib71","doi-asserted-by":"crossref","first-page":"58007","DOI":"10.18632\/oncotarget.11157","article-title":"Therapeutic implication of HER2 in advanced biliary tract cancer","volume":"7","author":"Nam","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.jhep.2026.02.030_bib72","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.02.030_bib73","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.jhep.2026.02.030_bib74","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.jhep.2026.02.030_bib75","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.jhep.2026.02.030_bib76","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.jhep.2026.02.030_bib77","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jhep.2026.02.030_bib78","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jhep.2026.02.030_bib79","article-title":"Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer","volume":"39","author":"Hong","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.02.030_bib80","doi-asserted-by":"crossref","first-page":"S787","DOI":"10.1016\/j.annonc.2023.09.2405","article-title":"1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon","year":"2023","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jhep.2026.02.030_bib81","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/2159-8290.CD-21-1119","article-title":"Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements","volume":"12","author":"Schram","year":"2022","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.jhep.2026.02.030_bib82","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of zenocutuzumab in NRG1 fusion-positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.02.030_bib83","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.02.030_bib84","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/14712598.2025.2556903","article-title":"An evaluation of zanidatamab, a novel, anti-HER2 biparatopic antibody, for the treatment of biliary tract cancer","volume":"25","author":"Yoon","year":"2025","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.jhep.2026.02.030_bib85","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/s41467-023-37029-3","article-title":"An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity","volume":"14","author":"Weisser","year":"2023","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.jhep.2026.02.030_bib86","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jhep.2026.02.030_bib87","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4091","article-title":"Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study","volume":"42","author":"Pant","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.jhep.2026.02.030_bib88","volume":"35","author":"Mercade","year":"2024","journal-title":"62tip Herizon-btc-302: A Phase Study Zanidatamab Standard-of-care (Soc) Therapy Vs SOC Alone First-line (1l) Treatment Human Epidermal Growth Factor Receptor 2 (Her2)-positive Advanced\/metastatic Biliary Tract Cancer (Btc)"},{"key":"10.1016\/j.jhep.2026.02.030_bib89","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.02.030_bib90","volume":"42","author":"Oh","year":"2024","journal-title":"Trastuzumab deruxtecan (T-dxd) patients (Pts) HER2-expressing biliary tract Cancer (Btc) Pancreat Cancer (Pc) Outcomes DESTINY-PanTumor02 (Dp-02)"},{"key":"10.1016\/j.jhep.2026.02.030_bib91","volume":"35","author":"Ikeda","year":"2024","journal-title":"Annals of Oncol"},{"key":"10.1016\/j.jhep.2026.02.030_bib92","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.jhep.2026.02.030_bib93","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1158\/2159-8290.CD-25-1457","article-title":"Rethinking cancer drug development through tumor-agnostic precision medicine","volume":"15","author":"Subbiah","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2026.02.030_bib94","doi-asserted-by":"crossref","unstructured":"Javle M. et al. Biliary cancer: utility of next-generation sequencing for clinical management Cancer. 122:3838\u20133847. doi:10.1002\/cncr.30254.","DOI":"10.1002\/cncr.30254"},{"issue":"17","key":"10.1016\/j.jhep.2026.02.030_bib95","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2026.02.030_bib96","doi-asserted-by":"crossref","unstructured":"Hong D. S. et al KRAS(G12C) inhibition with sotorasib in advanced solid tumors N Engl J Med. 383:1207\u20131217. doi:10.1056\/NEJMoa1917239.","DOI":"10.1056\/NEJMoa1917239"},{"key":"10.1016\/j.jhep.2026.02.030_bib97","doi-asserted-by":"crossref","unstructured":"Bekaii-Saab T. S. et al KRYSTAL-1: updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation J Clin Oncol. 40:519\u2013519. doi:10.1200\/JCO.2022.40.4_suppl.519.","DOI":"10.1200\/JCO.2022.40.4_suppl.519"},{"key":"10.1016\/j.jhep.2026.02.030_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2026.03.020","article-title":"Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma","author":"Entrialgo-Cadierno","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2026.02.030_bib99","doi-asserted-by":"crossref","unstructured":"Schneider M. et al. The PROTACtable genome Nat Rev Drug Discov. 20:789\u2013797. doi:10.1038\/s41573-021-00245-x.","DOI":"10.1038\/s41573-021-00245-x"},{"key":"10.1016\/j.jhep.2026.02.030_bib100","doi-asserted-by":"crossref","unstructured":"Moore A. R., Rosenberg, S. C, McCormick, F & Malek, S RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 19:533\u2013552. doi:10.1038\/s41573-020-0068-6.","DOI":"10.1038\/s41573-020-0068-6"},{"key":"10.1016\/j.jhep.2026.02.030_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104535","article-title":"Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data","volume":"10","author":"Ikushima","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.jhep.2026.02.030_bib102","doi-asserted-by":"crossref","unstructured":"Karikari C. A. et al Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers Mol Cancer Ther. 4:1860\u20131866. doi:10.1158\/1535-7163.MCT-05-0103.","DOI":"10.1158\/1535-7163.MCT-05-0103"},{"key":"10.1016\/j.jhep.2026.02.030_bib103","doi-asserted-by":"crossref","unstructured":"Kryukov G. V. et al MTAP deletion confers enhanced dependency PRMT5 arginine methyltransferase Cancer Cell Sci. 351:1214\u20131218. doi:10.1126\/science.aad5214.","DOI":"10.1126\/science.aad5214"},{"key":"10.1016\/j.jhep.2026.02.030_bib104","doi-asserted-by":"crossref","unstructured":"Gounder M. et al. MAT2A inhibitor AG-270\/S095033 in patients with advanced malignancies: a phase I trial Nature Communications. 16:423. doi:10.1038\/s41467-024-55316-5.","DOI":"10.1038\/s41467-024-55316-5"},{"key":"10.1016\/j.jhep.2026.02.030_bib105","doi-asserted-by":"crossref","unstructured":"Wade M. Li, Y.-C. Wahl, G M MDM2, MDMX and p53 in oncogenesis and cancer therapy Nat Rev Cancer. 13:83\u201396. doi:10.1038\/nrc3430.","DOI":"10.1038\/nrc3430"},{"key":"10.1016\/j.jhep.2026.02.030_bib106","doi-asserted-by":"crossref","unstructured":"Gollner A. et al. Discovery and characterization of brigimadlin, a novel and highly potent MDM2-p53 antagonist suitable for intermittent dose schedules Mol Cancer Ther. 23:1689\u20131702. doi:10.1158\/1535-7163.MCT-23-0783.","DOI":"10.1158\/1535-7163.MCT-23-0783"},{"key":"10.1016\/j.jhep.2026.02.030_bib107","doi-asserted-by":"crossref","unstructured":"Yamamoto N. et al. Efficacy and safety of the MDM2-p53 antagonist brigimadlin (BI 907828) in patients with advanced biliary tract cancer: a case series Onco Targets Ther. 17:267\u2013280. doi:10.2147\/OTT.S440979.","DOI":"10.2147\/OTT.S440979"},{"key":"10.1016\/j.jhep.2026.02.030_bib108","doi-asserted-by":"crossref","unstructured":"Yoo C. et al. Brightline-2: a phase IIa\/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors Future Oncol. 20:1069\u20131077. doi:10.2217\/fon-2023-0963.","DOI":"10.2217\/fon-2023-0963"},{"key":"10.1016\/j.jhep.2026.02.030_bib109","doi-asserted-by":"crossref","unstructured":"Date A. et al. Affinity-based protein profiling of MDM2 inhibitor Navtemadlin Chem Sci. 16:6886\u20136894. doi:10.1039\/d5sc00120j.","DOI":"10.1039\/D5SC00120J"},{"key":"10.1016\/j.jhep.2026.02.030_bib110","doi-asserted-by":"crossref","unstructured":"Zhang X. et al. A first-in-human phase I study of a novel MDM2\/p53 inhibitor alrizomadlin in advanced solid tumors ESMO Open. 9:103636. doi:10.1016\/j.esmoop.2024.103636.","DOI":"10.1016\/j.esmoop.2024.103636"},{"key":"10.1016\/j.jhep.2026.02.030_bib111","doi-asserted-by":"crossref","unstructured":"Guerlavais V. et al. Discovery of sulanemadlin (ALRN-6924), the first cell-permeating, stabilized alpha-helical peptide in clinical development J Med Chem. 66:9401\u20139417. doi:10.1021\/acs.jmedchem.3c00623.","DOI":"10.1021\/acs.jmedchem.3c00623"},{"key":"10.1016\/j.jhep.2026.02.030_bib112","unstructured":"The landscape of MET mutations in Chinese biliary tract cancers. - ASCO [Internet]. [cited 2026 Feb 1]. Available from: https:\/\/www.asco.org\/abstracts-presentations\/186519."},{"key":"10.1016\/j.jhep.2026.02.030_bib113","doi-asserted-by":"crossref","unstructured":"Lefler D. S. Tierno, M B Bashir, B Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature Cancer Biol Ther. 23:112\u2013116. doi:10.1080\/15384047.2022.2029128.","DOI":"10.1080\/15384047.2022.2029128"},{"key":"10.1016\/j.jhep.2026.02.030_bib114","doi-asserted-by":"crossref","unstructured":"Turpin A. Descarpentries, C. Gregoire, V Farchi, et al. Response to capmatinib in a MET fusion-positive cholangiocarcinoma Oncologist. 28:80\u201383. doi:10.1093\/oncolo\/oyac194.","DOI":"10.1093\/oncolo\/oyac194"},{"key":"10.1016\/j.jhep.2026.02.030_bib115","doi-asserted-by":"crossref","unstructured":"Reichinger A. et al. Exceptional sustained long-term complete response to Tepotinib in a MET-amplified advanced intrahepatic biliary tract cancer failing Durvalumab plus Cisplatin and Gemcitabine Oncologist. 29:1090\u20131094. doi:10.1093\/oncolo\/oyae265.","DOI":"10.1093\/oncolo\/oyae265"},{"key":"10.1016\/j.jhep.2026.02.030_bib116","doi-asserted-by":"crossref","unstructured":"Murciano-Goroff Y. R. In: Vol. 36. p. S598\u2013S599. doi:10.1016\/j.annonc.2025.08.1487.","DOI":"10.1016\/j.annonc.2025.08.1487"},{"key":"10.1016\/j.jhep.2026.02.030_bib117","doi-asserted-by":"crossref","unstructured":"Dhyani A. et al. Abstract 724: target identification for antibody-drug-conjugate (ADC) therapy in biliary tract cancers (BTC) Cancer Res. 85:724\u2013724. doi:10.1158\/1538-7445.Am2025-724.","DOI":"10.1158\/1538-7445.AM2025-724"},{"key":"10.1016\/j.jhep.2026.02.030_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.2228","article-title":"1600O Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a phase I trial","volume":"36","author":"Patel","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jhep.2026.02.030_bib119","first-page":"200","article-title":"Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials","volume":"112","author":"Lamarca","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.jhep.2026.02.030_bib120","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2026.02.030_bib121","first-page":"50","article-title":"New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe","author":"Rimassa","year":"2025","journal-title":"The Lancet Reg Health \u2013 Europe"},{"issue":"10","key":"10.1016\/j.jhep.2026.02.030_bib122","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206007","article-title":"The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers","volume":"13","author":"Lamarca","year":"2018","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.jhep.2026.02.030_bib123","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092854","article-title":"Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.jhep.2026.02.030_bib124","doi-asserted-by":"crossref","first-page":"106306","DOI":"10.1016\/j.esmoop.2026.106306","article-title":"Phase III trial of infigratinib versus gemcitabine\/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301","volume":"11","author":"Abou-Alfa","year":"2026","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.jhep.2026.02.030_bib125","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.jhep.2026.02.030_bib126","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jhep.2024.10.020","article-title":"Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer","volume":"82","author":"Hwang","year":"2025","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.jhep.2026.02.030_bib127","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.annonc.2022.09.150","article-title":"The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer","volume":"33","author":"Berchuck","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jhep.2026.02.030_bib128","article-title":"Optimization of bile preparation for liquid biopsy in cholangiocarcinoma focusing on circulating tumor DNA and protein stability","volume":"15","author":"Han","year":"2025","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jhep.2026.02.030_bib129","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.jhep.2026.02.030_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104540","article-title":"Cet al. Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10\u2014precision Medicine)","volume":"10","author":"Malka","year":"2025","journal-title":"ESMO Open"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826001285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826001285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:55:03Z","timestamp":1789491303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826001285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":130,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0168827826001285"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.02.030","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic therapy of biliary tract cancer: The road to personalised strategies","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}